Biotricity Inc. filings document a Nevada medical technology issuer focused on remote cardiac monitoring, diagnostic and post-diagnostic solutions, and Technology-as-a-Service healthcare workflows. Form 8-K reports include financial-results releases and material definitive agreements tied to the company’s operating updates and capital structure.
The filing record also covers registration-statement disclosures, common stock, warrants, options and preferred-stock terms. Recent capital-structure disclosures include exchange agreements, a certificate of designation for Series C Preferred Stock, voting rights and conversion mechanics, alongside governance and risk information relevant to the company’s public reporting obligations.
Biotricity Inc. ownership update: Ionic Ventures, Ionic Management, Brendan O'Neil and Keith Coulston report beneficial ownership of 3,096,987 shares of common stock, representing 9.99% of the class based on February 11, 2026 outstanding shares. The position includes 532,757 directly or indirectly held common shares and conversion rights from 335 shares of Series B Convertible Preferred Stock that could produce additional "Conversion Shares" subject to a 9.99% Blocker in the Certificate of Designations.
The filing explains conversion mechanics: up to $2,250,000 of Preferred Stock could convert into 9,533,898 Conversion Shares at an $0.236 Alternate Conversion Price as of March 31, 2026, but the 9.99% blocker and limits on Conversion Notices constrain how many conversion shares are deemed beneficially owned for reporting. Shared voting and dispositive power over the reported shares is attributed to Ionic, Ionic Management, Mr. O'Neil and Mr. Coulston.
Biotricity Inc. entered exchange agreements on May 1, 2026 with holders of 14,144,325 common shares, options for 3,992,427 shares, and warrants for 1,436,216 shares. These securities were exchanged for 1,957,297 shares of newly created Series C Preferred Stock on a ten‑for‑one basis.
The company designated 2,100,000 Series C Preferred shares, each carrying 40 votes. After any equity financing raising at least $15 million, outstanding Series C will automatically convert into 59.6% of Biotricity’s common stock. If no such financing occurs by March 31, 2028, each Series C share may convert into 10 common shares.
Biotricity Inc. reported solid third-quarter fiscal 2026 results, with revenue rising 10.2% to $4 million from $3.6 million a year earlier. The company highlighted its third consecutive quarter of positive EBITDA and net operating income, reflecting growing adoption of its remote cardiac monitoring solutions.
Gross margin improved to 81.5% from 76.4%, helped by a larger recurring technology-fee base and AI-driven efficiencies. Net loss narrowed to $1.1 million, or $0.042 per share, compared with $1.3 million, or $0.054 per share. Management also pointed to strong customer retention above 90% and ongoing international expansion.
Biotricity Inc. reported higher revenue and narrower losses but remains under significant financial strain. For the nine months ended December 31, 2025, revenue rose to $11.7 million from $10.1 million, with gross profit increasing to $9.5 million. Net loss attributable to common stockholders improved to $2.7 million from $9.9 million, reflecting lower operating expenses and reduced accretion and derivative costs.
Despite this progress, the balance sheet is highly leveraged. Total assets were $5.7 million against $38.2 million in total liabilities, producing a stockholders’ deficiency of $34.2 million and a working capital deficit of $18.8 million. Cash was only $256,357, and operating activities used $0.7 million of cash over nine months.
Management states that recurring losses, a large accumulated deficit of $142.1 million, and liquidity constraints raise substantial doubt about Biotricity’s ability to continue as a going concern. The company expects to fund operations through continued revenue growth and additional equity and debt financings, but there is no assurance it can secure sufficient capital or avoid further dilution.
Biotricity Inc. shareholder Ionic Ventures and its affiliates report updated beneficial ownership of 3,035,960 shares of common stock. This total includes 443,681 shares of common stock held by Ionic Ventures and up to 2,592,279 shares issuable upon conversion of Series B preferred stock.
The filing explains that further conversions of the preferred stock are limited by a 9.99% beneficial ownership cap in Biotricity’s certificate of designations, which restricts how many conversion shares can be counted. The ownership figures are based on 27,797,711 common shares outstanding as of December 12, 2025, and are jointly reported by Ionic Ventures, Ionic Management, Brendan O’Neil, and Keith Coulston.
Biotricity Inc. is registering up to 44,117,647 shares of common stock in a primary offering at an assumed price of $0.34 per share. The medical technology company provides remote cardiac monitoring solutions such as its FDA-cleared Bioflux and Biotres devices, a direct-to-consumer Bioheart monitor, and the Biocare disease management platform, aiming to build recurring technology-fee revenue from cardiac diagnostics and chronic care.
The company has expanded sales to 33 U.S. states and is investing in AI-driven analytics, supported in part by a $238,703 NIH grant, while partnering with major cloud providers for its cardiac AI model. However, Biotricity carries substantial financial risk, including approximately $21.1 million of indebtedness as of March 31, 2023, a cash balance of about $308,460, an accumulated deficit of $140.97 million, and a working capital deficiency of about $18.08 million as of September 30, 2025.
Auditors have expressed substantial doubt about its ability to continue as a going concern, and the company faces a Nasdaq delisting process after failing to meet the $35 million market value of listed securities requirement. The S-1 outlines numerous risks, including heavy leverage, the need for additional capital, potential dilution from preferred stock and convertible notes, reimbursement and regulatory uncertainties, intense competition in cardiac monitoring, and volatility and limited liquidity in its common stock.
Biotricity Inc. reported that it has released its financial results for the period ended September 30, 2025. The company announced these results through a press release dated November 14, 2025, which is included as Exhibit 99.1. The notice clarifies that this earnings information is being furnished under a current report and is not deemed filed for liability purposes under the securities laws unless specifically incorporated by reference elsewhere.
Ionic Ventures, LLC, Ionic Management, LLC, Brendan O’Neil, and Keith Coulston filed a Schedule 13G/A (Amendment No. 5) disclosing beneficial ownership of 2,926,171 shares of Biotricity Inc. (BTCY), representing 9.9% of the class, based on 26,567,769 shares outstanding as of August 13, 2025.
The position comprises 202,937 common shares and up to 2,723,234 shares issuable upon conversion of Series B Convertible Preferred Stock, subject to a 9.99% beneficial ownership limitation in the Certificate of Designations. As of September 30, 2025, up to 4,245,283 shares could be issuable within sixty days at an Alternate Conversion Price of $0.53, though portions are not deemed beneficially owned due to blocker and conversion notice limits. The reporting persons have shared voting and dispositive power over 2,926,171 shares and no sole power. They certify the holdings are not for the purpose of changing or influencing control.
Biotricity (BTCY) filed its quarterly report for the period ended September 30, 2025. The company grew revenue to $3,885,795 for the quarter (from $3,266,846) and $7,759,788 for the six months (from $6,468,589). Gross profit rose to $3,181,498 in the quarter, and Biotricity posted operating income of $273,819 compared with a prior-year operating loss. Net loss narrowed to $(690,913) for the quarter and $(1,362,890) year‑to‑date.
Liquidity remains tight with cash of $308,460 and total liabilities of $37,984,860, resulting in a stockholders’ deficit of $(33,412,378). Management disclosed a working capital deficiency of $18,077,790 and stated that these conditions raise substantial doubt about the company’s ability to continue as a going concern. As of November 13, 2025, there were 27,797,711 common shares outstanding, plus 160,672 exchangeable shares, equivalent to 27,958,383 voting securities.